ArticleJournal of racial and ethnic health disparities2025
Triple-Negative Breast Cancer, Recurrence, and Survival Outcomes in Young Black Women.
Article in Journal of racial and ethnic health disparities, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTriple-negative breast cancer (TNBC) accounts for 40-50% of breast cancers in young Black women. Black women have an increased risk of death due to TNBC than White women; whether age contributes to worse outcomes in the setting of a high-risk tumor subtype is unclear.
methodsOur retrospective review of an institutional database identified Black women with operable TNBC from 2005 to 2020. Clinicopathologic, treatment, and outcome variables in women aged < 40 (young adults [YAs] cohort) were compared to those ≥ 40 years using Cox proportional hazard models. Kaplan-Meier method estimated overall survival (OS) and breast cancer-specific survival (BCSS).
resultsWe identified 397 Black women with a median age of 55 (range 23-88); 39 (9.8%) were < 40 and 358 (90.2%) were ≥ 40. The YA cohort were more likely to have a BRCA mutation and present with a physical finding and more advanced clinical stage (all p < 0.01). Compared with women ≥ 40 years, those < 40 were more likely to receive mastectomy (61.5% vs. 31.3%; p < 0.001) and neoadjuvant chemotherapy (46.2% vs. 26.7%; p = 0.05), and not receive adjuvant radiotherapy (35.9% vs. 18.8%; p = 0.008). At a median follow-up of 6.2 years, the 5-year OS and BCSS rates were 81.2% and 84.0% in women < 40 years old, and 80.9% and 85.3% in those ≥ 40 (p = 0.45 and p = 0.75, respectively).
conclusionYoung age at diagnosis in Black women with TNBC was not an independent predictor of locoregional recurrence, distant recurrence, OS, or BCSS despite being associated with higher stage of disease.
Indexed as
Identifiers
41037226What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.